Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(incorporated in the Cayman Islands with limited liability)
(Stock Code: 2561)

SUPPLEMENT ANNOUNCEMENT CONNECTED TRANSACTION – COMMERCIAL SUPPLY FRAMEWORK AGREEMENT

Reference is made to the announcement of Visen Pharmaceuticals (the "Company") dated June 12, 2025 and the circular of the Company dated June 12, 2025 in relation to connected transactions contemplated under the Commercial Supply Framework Agreement entered into between VISEN HK and Ascendis Europe (the "Previous Announcement and Circular").

Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Previous Announcement and Circular.

The Company would like to supplement the Previous Announcement and Circular with the following information in respect of the parties to the Commercial Supply Framework Agreement.

Parties to the Commercial Supply Framework Agreement

Pursuant to the Commercial Supply Framework Agreement, VISEN HK has agreed to purchase, by itself or its subsidiaries, the Drug Packages, auto-injectors, and applicable ancillary products from Ascendis Europe and/or its subsidiaries. On August 29, 2025, VISEN HK and Ascendis Europe entered into an amendment agreement to the Commercial Supply Framework Agreement (the "Amendment Agreement"), pursuant to which it was agreed that, VISEN HK (by itself or its subsidiaries) may purchase the relevant products from Ascendis A/S and/or its subsidiaries (the "Ascendis Group"). Under the Amendment Agreement, a broader scope of entities would be allowed to supply products pursuant to the terms thereto.

The Amendment Agreement was entered into mainly due to the internal arrangements of Ascendis Group, to better allocate internal resources to supply products from different entities within the Group. Such arrangement also provides more flexibility for both VISEN and Ascendis Group, and is in the interest of both parties.

Save as disclosed above, all information set forth in the Commercial Supply Framework Agreement and the Previous Announcement and Circular remains unchanged. This announcement is supplemental to and should be read in conjunction with the Previous Announcement and Circular.

By order of the Board
VISEN Pharmaceuticals
Mr. LU An-Bang
Executive Director and Chief Executive Officer

Hong Kong, August 31, 2025

As at the date of this announcement, the board of directors of the Company comprises (i) Mr. LU An-Bang as executive director; (ii) Mr. FU Shan and Mr. CAO Yibo as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan, Ms. NI Hong and Mr. ZHANG Qing as independent non-executive directors.